Back to mobile site

JPMorgan Reiterates Overweight Rating on PTC Therapeutics (PTCT)

December 2, 2024 4:14 PM EST Send to a Friend
JPMorgan analyst Eric Joseph reiterated an Overweight rating and $62.00 price target on PTC Therapeutics (NASDAQ: PTCT)The analyst comments "This ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login